-
Mashup Score: 0
Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Michael B. Atkins, MD, of @LombardiCancer, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma #melnm https://t.co/UHshRAgUW5 https://t.co/gkA8ybkhBU